Dr. Frankie Ann Holmes on Duel Anti-HER2-Directed Therapy in Breast Cancer

Frankie Ann Holmes, MD
Published: Tuesday, Aug 09, 2016



Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant duel HER2-directed therapy in breast cancer.

Neoadjuvant directed therapy is seeing extremely high total pathological complete response rates. For patients whose tumors are greater than 2 centimeters or are node-positive, dual anti–HER2-directed therapy with trastuzumab and pertuzumab (Perjeta) either with a taxane carboplatin backbone or, with the anthracycline cytoxin then taxane backbone, have shown to be very effective and are the optimal choices of therapy for those patients, said Holmes.
 
Patients that are ER-negative that have the HER-enriched phenotype have much more aggressive disease and may need the duel HER2-targeted therapy, while patients with more Luminal disease may not, said Holmes. Questions still remain regarding treatment for patients that do not meet the criteria for duel HER2-directed therapy.
 
Biomarkers will need to be discovered to determine which patients need maximum therapy, which comes with additional costs and toxicities, and which ones do not, she said.
 


Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant duel HER2-directed therapy in breast cancer.

Neoadjuvant directed therapy is seeing extremely high total pathological complete response rates. For patients whose tumors are greater than 2 centimeters or are node-positive, dual anti–HER2-directed therapy with trastuzumab and pertuzumab (Perjeta) either with a taxane carboplatin backbone or, with the anthracycline cytoxin then taxane backbone, have shown to be very effective and are the optimal choices of therapy for those patients, said Holmes.
 
Patients that are ER-negative that have the HER-enriched phenotype have much more aggressive disease and may need the duel HER2-targeted therapy, while patients with more Luminal disease may not, said Holmes. Questions still remain regarding treatment for patients that do not meet the criteria for duel HER2-directed therapy.
 
Biomarkers will need to be discovered to determine which patients need maximum therapy, which comes with additional costs and toxicities, and which ones do not, she said.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x